Back

The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

28 August 2016 (14:00 - 14:15)
Organised by:
Congress Presentation Part of: Clinical Trial Update Prevention Epidemiology, lipids ESC Premium Access ESC Congress 2016

About the speaker

Photo
Associate Professor Ajay Gupta

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial
Doctor A. Vallejo-Vaz (Seville, ES)
Presentation thumbnail
Lipid Levels and CV Outcome with CETP Inhibition by Evacetrapib in the ACCELERATE Trial
Professor A. Lincoff (Cleveland, US)
Slides Video
Presentation thumbnail
The Benefit of Adding Ezetimibe to Statin Therapy in Patients With or Without prior Coronary Artery Bypass Graft surgery in the IMPROVE-IT Trial
Professor A. Eisen (Petah Tikva, IL)
Slides Video
Presentation thumbnail
First-in-man study of a pacemaker-mediated programmable hypertension control therapy
Professor P. Neuzil (Prague, CZ)
Slides Video
Presentation thumbnail
The relationship between severe hypoglycaemic events and cardiovascular outcomes is bidirectional: novel results from TECOS
Professor E. Standl (Munich, DE)

Access the full session

Session thumbnail
Clinical Trial Update Prevention

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources